Weight loss of 14.5%! After the failure of its Alzheimer's trial, Novo Nordisk released positive data on a new weight-loss drug, boosting its stock price.

```

Clinical trial data released by Novo Nordisk for the new-generation diabetes drug amycretin shows that the drug achieves significant weight loss while lowering blood sugar, giving a boost to the Danish pharmaceutical company whose market value has halved this year.

On Tuesday, trial results released by Novo Nordisk showed that weekly injections of amycretin can help patients lose up to 14.5% of their body weight in 36 weeks, while daily oral formulations can achieve up to 10.1% weight loss.

The news drove Novo Nordisk’s U.S. shares up over 4.6%, recovering most of the losses caused by yesterday’s failed Ozempic drug trial.

WallstreetCN reported that on Monday Novo Nordisk announced the oral version of Ozempic failed to slow the progression of Alzheimer’s disease in two large clinical trials. Based on cognitive assessment results, patients taking the drug did not show significant improvement.

Regarding the results of the amycretin trial, Bloomberg Industry Research analyst Michael Shah said that although direct comparison is difficult due to differences in clinical trial design, Novo Nordisk’s drug performed well in terms of weight loss relative to Eli Lilly’s Zepbound and its next-generation oral drug orforglipron.

Shah added:

However, patients in the Novo Nordisk trial were heavier, and initial weight loss can be relatively easier for heavier individuals.

Shah believes:

In large late-stage studies, amycretin’s impact on blood sugar is less than Eli Lilly’s drug, but detailed data, including side effects, will be critical.

Reportedly, Amycretin is a key part of Novo Nordisk's new generation of drug combinations, integrating two weight loss mechanisms into a single molecule.

After losing its lead in the obesity treatment field to American competitor Eli Lilly, Novo Nordisk needs next-generation drugs to improve its competitive position.

Novo Nordisk plans to launch late-stage clinical trials of amycretin in type 2 diabetes patients next year, but analysts believe results are unlikely to be delivered before 2028, so this does not immediately solve Novo Nordisk’s product line issues.

Risk Disclaimer and Limitation of LiabilityThe market has risks, and investment should be done cautiously. This article does not constitute individual investment advice and does not take into account the unique investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, viewpoints, or conclusions in this article are suitable for their specific conditions. Investment based on this, responsibility is solely your own. ```